Collegium Pharmaceutical, Inc. Income Taxes Paid
Collegium Pharmaceutical, Inc. (COLL) reported Income Taxes Paid of $37.47 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:IncomeTaxesPaidNet · last filed 2026-08-06
- Collegium Pharmaceutical, Inc. income taxes paid, net for the quarter ending 2026-06-30 was $37.43M, a 25.53% increase year-over-year.
- Collegium Pharmaceutical, Inc. income taxes paid, net for the quarter ending 2026-03-31 was $44.00K, a 98.21% decline year-over-year.
- Collegium Pharmaceutical, Inc. income taxes paid, net for the quarter ending 2025-12-31 was $12.28M, a 1877.46% increase year-over-year.
- Collegium Pharmaceutical, Inc. income taxes paid, net for the quarter ending 2025-09-30 was $15.49M, a 0.64% decline year-over-year.
- Collegium Pharmaceutical, Inc. income taxes paid, net for fiscal 2025 was $60.04M, a 15.26% increase from fiscal 2024.
- Collegium Pharmaceutical, Inc. income taxes paid, net for fiscal 2024 was $52.09M, a 115.20% increase from fiscal 2023.
- Collegium Pharmaceutical, Inc. income taxes paid, net for fiscal 2023 was $24.20M, a 132.74% increase from fiscal 2022.
- Collegium Pharmaceutical, Inc. income taxes paid, net for fiscal 2022 was $10.40M, a 246.09% increase from fiscal 2021.
| Period end | Income Taxes Paid, Net 3 month | Income Taxes Paid, Net 6 month | Income Taxes Paid, Net 9 month | Income Taxes Paid, Net 12 month |
|---|---|---|---|---|
| 2026-06-30 | $37.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $37.47M 10-Q · filed 2026-08-06 | $49.75M derived: sum of 3 quarters · filed 2026-08-06 | $65.24M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $44.00K 10-Q · filed 2026-05-07 | $12.32M derived: sum of 2 quarters · filed 2026-05-07 | $27.81M derived: sum of 3 quarters · filed 2026-05-07 | $57.63M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $12.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $27.77M derived: sum of 2 quarters · filed 2026-02-26 | $57.59M derived: sum of 3 quarters · filed 2026-08-06 | $60.04M 10-K · filed 2026-02-26 |
| 2025-09-30 | $15.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $45.30M derived: sum of 2 quarters · filed 2026-08-06 | $47.76M 10-Q · filed 2025-11-06 | $48.38M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $29.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $32.27M 10-Q · filed 2026-08-06 | $32.89M derived: sum of 3 quarters · filed 2026-08-06 | $48.48M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $2.46M 10-Q · filed 2026-05-07 | $3.08M derived: sum of 2 quarters · filed 2026-05-07 | $18.66M derived: sum of 3 quarters · filed 2026-05-07 | $54.37M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $621.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $16.21M derived: sum of 2 quarters · filed 2026-02-26 | $51.92M derived: sum of 3 quarters · filed 2026-02-26 | $52.09M 10-K · filed 2026-02-26 |
| 2024-09-30 | $15.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $51.30M derived: sum of 2 quarters · filed 2025-11-06 | $51.47M 10-Q · filed 2025-11-06 | $58.38M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $35.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $35.88M 10-Q · filed 2025-08-07 | $42.79M derived: sum of 3 quarters · filed 2026-02-26 | $50.08M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $173.00K 10-Q · filed 2025-05-08 | $7.08M derived: sum of 2 quarters · filed 2026-02-26 | $14.37M derived: sum of 3 quarters · filed 2026-02-26 | $23.64M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $6.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $14.19M derived: sum of 2 quarters · filed 2026-02-26 | $23.46M derived: sum of 3 quarters · filed 2026-02-26 | $24.20M 10-K · filed 2026-02-26 |
| 2023-09-30 | $7.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $16.55M derived: sum of 2 quarters · filed 2024-11-07 | $17.29M 10-Q · filed 2024-11-07 | $17.66M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $9.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $10.01M 10-Q · filed 2024-08-08 | $10.37M derived: sum of 3 quarters · filed 2025-02-27 | $13.63M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $743.00K 10-Q · filed 2024-05-09 | $1.11M derived: sum of 2 quarters · filed 2025-02-27 | $4.37M derived: sum of 3 quarters · filed 2025-02-27 | $9.03M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $363.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $3.62M derived: sum of 2 quarters · filed 2025-02-27 | $8.29M derived: sum of 3 quarters · filed 2025-02-27 | $10.40M 10-K · filed 2025-02-27 |
| 2022-09-30 | $3.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $7.92M derived: sum of 2 quarters · filed 2023-11-07 | $10.04M 10-Q · filed 2023-11-07 | $10.71M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $4.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $6.78M 10-Q · filed 2023-08-03 | $7.45M derived: sum of 3 quarters · filed 2024-02-22 | $8.90M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $2.11M 10-Q · filed 2023-05-04 | $2.79M derived: sum of 2 quarters · filed 2024-02-22 | $4.24M derived: sum of 3 quarters · filed 2024-02-22 | $4.70M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $676.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $2.13M derived: sum of 2 quarters · filed 2024-02-22 | $2.59M derived: sum of 3 quarters · filed 2024-02-22 | $3.00M 10-K · filed 2024-02-22 |
| 2021-09-30 | $1.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $1.91M derived: sum of 2 quarters · filed 2022-11-03 | $2.33M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $458.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $876.00K 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $418.00K 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $483.00K 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |